89bio, Inc. (ETNB)
NASDAQ: ETNB · Real-Time Price · USD
8.76
+0.38 (4.53%)
Nov 22, 2024, 4:00 PM EST - Market closed
89bio Employees
89bio had 70 employees as of December 31, 2023. The number of employees increased by 25 or 55.56% compared to the previous year.
Employees
70
Change (1Y)
25
Growth (1Y)
55.56%
Revenue / Employee
n/a
Profits / Employee
-$4,128,000
Market Cap
1.03B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 70 | 25 | 55.56% |
Dec 31, 2022 | 45 | 4 | 9.76% |
Dec 31, 2021 | 41 | 14 | 51.85% |
Dec 31, 2020 | 27 | 7 | 35.00% |
Dec 31, 2019 | 20 | - | - |
Related Stocks
Company Name | Employees |
---|---|
The Pennant Group | 5,791 |
OPKO Health | 3,930 |
AMN Healthcare Services | 3,585 |
Weave Communications | 844 |
Gyre Therapeutics | 593 |
Vir Biotechnology | 587 |
Collegium Pharmaceutical | 197 |
Cogent Biosciences | 164 |
ETNB News
- 8 days ago - 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024 - GlobeNewsWire
- 10 days ago - 89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 11 days ago - 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 18 days ago - 89bio to Participate in the UBS Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - 89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024 - GlobeNewsWire
- 6 weeks ago - 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - 89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference - GlobeNewsWire
- 2 months ago - 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer - GlobeNewsWire